索拉非尼联合肝动脉栓塞治疗兔肝癌的研究

An experimental study of rabbits with liver cancer treated with sorafenib combined with transcatheter arterial chemoembolization

目的 观察索拉非尼联合肝动脉栓塞(TACE)对兔肝癌模型的治疗效果。方法 将20只种植VX-2肿瘤组织建模成功的实验兔随机分为实验组与对照组,建模后21 d均行TACE治疗,术后实验组给予索拉非尼灌胃治疗,对照组给予同等剂量生理盐水灌胃处理,连续干预14 d。测定比较两组谷丙转氨酶(ALT)、总胆红素(TBIL)水平、肿瘤体积、组织血管内皮生长因子(VEGF)、微血管密度(MVD,经由染色CD34细胞实现)。结果 两组术后3、14 d ALT、TBIL水平较术前均显著升高(P<0.05);实验组术后3、14 d ALT、TBIL水平均显著低于对照组(P<0.05)。实验组术后7、14 d肿瘤体积分别为(1.70±0.25)、(1.75±0.26) cm3,均小于对照组[(2.12±0.32)、(3.04±0.42) cm3],差异有统计学意义(P<0.05)。实验组术后第21天组织VEGF、CD34表达分别为(5.18±0.75)、(31.46±4.25),均显著低于对照组的(6.46±0.87)、(61.28±8.40),差异有统计学意义(P<0.05)。结论 索拉非尼联合TACE治疗兔VX-2肝癌有效,能明显抑制VEGF表达,减小微血管密度。

Objective To study the curative effect of sorafenib combined with transcatheter arterial chemoembolization (TACE) on rabbit liver cancer model.Methods VX-2 tumor tissues were directly implanted with microscopic tweezers. 20 rabbits were randomly divided into the experimental group and the control group. TACE was performed at 21 days after modeling. The experimental group was treated with intragastric administration of sorafenib after operation, while the control group was treated with intragastric administration of the same dose of normal saline, for 14 days. Levels of alanine aminotransferase (ALT) and total bilirubin (TBIL), tumor volume, vascular endothelial growth factor (VEGF) and microvessel density (MVD, achieved by staining CD34 cells) were determined and compared between both groups.Results The levels of ALT and TBIL in both groups were significantly increased at 3 days and 14 days after operation (P<0.05). The above levels in the experimental group were significantly lower than those in the control group (P<0.05). The tumor volume in the experimental group at 7 and 14 days after operation [(1.70±0.25) cm3 and (1.75±0.26) cm3] was significantly smaller than that in the control group [(2.12±0.32) cm3 and (3.04±0.42) cm3] (P<0.05). The expression levels of VEGF and CD34 in the experimental group on the 21st day after operation [(5.18±0.75) and (31.46±4.25)] were significantly lower than those in the control group [(6.46±0.87) and (61.28±8.40)] (P<0.05). Conclusion Sorafenib combined with TACE is effective in the treatment of rabbit VX-2 liver cancer. It can significantly inhibit the expression of VEGF and decrease the MVD.